

## **Lion Biotechnologies to Present at Cowen and Company's 35th Annual Healthcare Conference**

March 2, 2015 12:17 PM ET

LOS ANGELES, March 2, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO) announced that president and CEO Elma Hawkins, PhD, will present at Cowen and Company's 35<sup>th</sup> Annual Healthcare Conference on Wednesday, March 4, 2015. Dr. Hawkins will present at 8:40 a.m. EST.

A webcast of Dr. Hawkins' presentation will be available both live and on replay. The presentation will be available via webcast at <http://wsw.com/webcast/cowen22/lbio>. The live webcast and subsequent archived replay of Lion Biotechnologies' presentation will also be accessible via the Investors section of the Company's web site at <http://lbio.com/investors/> under "Recent Events."

### **About Lion Biotechnologies**

Lion Biotechnologies, Inc. is engaged in the development of T cells and engineered T cells for the treatment of various cancers. The company's lead product candidate, LN-144, is a ready-to-infuse, autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and the H. Lee Moffitt Cancer Center & Research Institute. For more information, please visit <http://www.lionbio.com>.

### **Forward Looking Statements**

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risks relating to the Company's ability to conduct its Phase 2 clinical trial in metastatic melanoma and to further successfully develop or commercialize the Company's TIL technologies. Additional risks and uncertainties are described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Relations  
The Trout Group  
Tricia Truehart  
646-378-2953  
[ttruehart@troutgroup.com](mailto:ttruehart@troutgroup.com)

Source: Lion Biotechnologies, Inc.

Released March 2, 2015